Sebastien Ladet, Affluent Medical - Next-Gen Prostheses Developer | LSI Europe '22

Transcription

Sebastien Ladet  0:00  

Good afternoon, everyone. So, I'm Sebastien Ladet, the CEO of Affluent Medical. At Africans, we refocus on, you know, debilitating diseases that are in structural health and neurology. And we focus this in creating the combinations of talent expertise from the medical wards, and differentiated solutions so that we can bring back patients to the normal life. So we have in our portfolios, three products, which are focused on sutures and urology, and we raised up to right now, I would say 75 to 80, millions, euro million euro. And with this particular portfolio, we have, we can address a market, a market that is around like 10 billion and growing double digits. We have around 75 patent families strengthening and protecting our portfolio today. And we have 60 Incredible employee walking in three sites across France and Italy to develop and bring this product to the market. We we've been public since 2021. And our first product will be on the market in 2024. And right now, our three products are in clinical stage. So let's talk about the problem we're trying to solve. The first part is in the structure or handouts franchise, when you look at like the mitral insufficiency, there was a huge prevalence from two to 12% of the population globally, that are suffering from that disease. And so there was only 4% of these people are being treated because like the invasive or the surgery is not adapted to the profile, there is two ways to treat that disease, first, the repair or replacing the valve. And so we have a we have a product for both of this particular approach. First, our mutual ring is very useful in a way that like is totally inflatable. And he helped us to manage directions of the mentor, rehabilitations we have right now 24 patients implanted into the clinical trial. And so we are targeting to finalize the recruitment of those patients in the year 2023. The second evolutions is a meta valve delivered through a transcatheter approach, which is helping to really approach a greater number of patients. The different stations of our valve that we'll discuss in a minute, is like mimics the anatomy call mitral valve today. The second problem we're focusing on is the urinary incontinence. There is also like a huge prevalence with around like more than one of the millions patients suffering from this disease that like have moderate to severe urinary incontinence. Today, they're like very few solutions on the market. And 30% of the patients get this device extracted because of this consult or the way it's being used. We have also like a design which is unique, which is also addressed the anatomy for men and women as like women represent 80% of the patients suffering from incontinence right now, this is not very well known disease in a way that like there was a lot of like an awareness misbelief and shame and who is not treated appropriately, we have a device here that I can bring like patients back to your normal life by providing a remote control devices. That is that is implanted through like a mini invasive procedure in 30 minutes, and that can be controlled by the patient they're easily boss of this opportunity and problems represents a total 10 billion opportunity growing double digits. So let's let's make a small focus on our current product. And this one is very important in the sense that like, it can help bringing back patients to do activities on a daily basis with the families. And so we have here like a unique design that can help us to address a greater portion of patients. We have the design that is with a D shape Manoli flat and an assymetric design preventing ut obstructions for example, or helping to have a natural limo dynamic during the heartbeats. The team designed a way to deliver through a transapical delivery system, which is very easy to use and help the surgeons to perform a simple procedure that takes around 10 minutes. Now, from the patient's point of view, as you can see there is a huge advantage of devices is that you respect the hemodynamic and the vortex of the blood in the same were used for the natural valves. So what you see on the left is an interest on showing the vortex of the blood. When there is no disease in the mitral valve, what you see on the right is kind of like a boiling vortex with a valve that has been most with the design that is mostly the rebates from the aortic valve today with a three leaf led design. And so these require more effort for the left ventricle to pump the blood house. And what you see in the middle is the vortex of the valve the team has been designing and that provide and mimics the vortex internally so there is a significant reductions of the effort of the left ventricle to pump the blood into the system. So this is something that like just after the surgery, but also like during the entire life of the patients will help to address more patients with fragile health conditions to get access to that treatment. Currently, we have a strong patent portfolio as I mentioned, 35 patent families, they are covering all the product we have in our portfolio, which is pretty unique at this stage to have such a big portfolio for small companies. And also on every specificity of the design of our product we have specific patterns which is reinforcing the productions we having. We are targeting the first product on the market in 2024 with our carriers, mitral rings, and then progressively will bring to market epi GYN and artists with a focus in Europe and the US for the urology and the mitral valve replacements. The market launch will be Kevin's from 24, 25 and 26. So at this stage the three products are in clinical stage and we are actively recruiting today for first in men with the mitral valve OBGYN. Obviously to design those right product we need like experienced team. And so we have people in the teams coming from different horizons small and large company with strong experience at a minimum 20 years in the industry. In order in terms of commercialization in terms of clinical experience, financial management, as well as like medical expertise and product development. Our people coming from the Remo Edwards, Medtronic, and Mackerts really make like a great team to bring this three product portfolio into the market. The vision set Affluent's with this portfolio is ready to build the foundation of a European medtech. And so, we do that based out of three pillar first the innovations with like highly differentiated product at critical stage. The fact that like by regrouping does different platform we can attract talent and experience people to deliver on the commitments we have been defining. And then the ability to globalize our approach by direct sale and distribution channel partners and deserialization and partnerships. So as I said at the beginning, at this stage, we raised 80 million euro and we're looking for the next round on investment we just closed on a capital increase two days ago of 6 million. But in order to increase the number of patients with our mitral valves, which require in between one 150 and 200 patients we're going to need next round and we are looking for 20 to 40 Millions euro to have investment. Thank you